General Information
Lurasidone is an orally administered substance that belongs to the class of atypical antipsychotic drugs (AAPD). These drugs are suggested to have less side effects in comparison to typical psychotic drugs. It is prescribed for the treatment of schizophrenia and bipolar depression ‘ specifically, for the treatment of depressive episodes associated with bipolar I disorder in adults when used alone or in combination with lithium or valproate. Lurasidone has been found to have a beneficial effect on cognitive performance in patients with acute psychosis. This suggests that lurasidone treatment may offer an approach for the prevention of cognitive impairment in individuals who are at risk for schizophrenia or related disorders involving cognitive impairment
About the API
US DMF